WuXi Biologics (Cayman) Inc. (2269.HK)
Manufactures biological drugs and provides research services for pharmaceutical companies worldwide.
39.32+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+25.4%
The outlook
WuXi Biologics trades at 39.32, sitting well above its 50- and 200-day moving averages in an uptrend. Analyst consensus leans Buy, with the average price target about 20% above the current price. The stock sits roughly 70% of the way through its 52-week range, trading at a trailing P/E of 29.3.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 23 analysts
Price trendAbove its 50- & 200-day averages
52-week range70% of the way from its 52-week low to high
Price targetAvg target +20% vs current price
Analyst price target
~12-month · 23 analysts47.07average target+19.7% vs now
Now 39.32
Low 30.61High 78.48
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$161.46B
52-wk high
44.00
52-wk low
28.48
50-day avg
34.48
200-day avg
35.08
Trailing P/E
29.3